


PRODUCT INFORMATION



Tibolone

Item No. 10006321

CAS Registry No.: 5630-53-5
Formal Name: 17 α -hydroxy-7 α -methyl-19-norpregn-5(10)-en-20-yn-3-one
Synonyms: 7 α -Methyl- $\Delta^{5,10}$ -norethindrone, Org OD 14
MF: C₂₁H₂₈O₂
FW: 312.5
Purity: \geq 98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: \geq 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tibolone is supplied as a crystalline solid. A stock solution may be made by dissolving the tibolone in the solvent of choice, which should be purged with an inert gas. Tibolone is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of tibolone in these solvents is approximately 2, 20, and 30 mg/ml, respectively.

Tibolone is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, tibolone should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Tibolone has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Tibolone is an estrogen-like compound used for the treatment of the symptoms associated with menopausal transition (i.e., climacteric symptoms) and also for the treatment of osteoporosis.¹ Three major metabolites of tibolone are responsible for its tissue selective mechanism of action. Conversion into 3 α - and 3 β -hydroxy-tibolone results in estrogenic effects in brain, vagina, and bone. The Δ^4 isomer has progestrogenic and androgenic effects and does not cause estrogenic stimulation in the endometrium.¹ A two-year longitudinal study indicates that low doses (1.25-2.5 mg) of tibolone effectively relieve climacteric symptoms and prevent loss of bone mass in early postmenopausal women.²

References

1. Kloosterboer, H.J. Tissue-selectivity: The mechanism of action of tibolone. *Maturitas* **48(Suppl 1)**, S30-S40 (2004).
2. Gambacciani, M., Ciaponi, M., Cappagli, B., et al. A longitudinal evaluation of the effect of two doses of tibolone on bone density and metabolism in postmenopausal women. *Gynecol. Endocrinol.* **18(1)**, 9-16 (2004).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/13/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM